Detalhe da pesquisa
1.
Outcome prioritization and preferences among older adults with cancer starting chemotherapy in a randomized clinical trial.
Cancer
; 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38630903
2.
Adjuvant Chemoradiation in Resected Biliary Adenocarcinoma: Evaluation of SWOG S0809 with a Large National Database.
Ann Surg Oncol
; 2024 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38443700
3.
Acute cancer-related symptoms and concerns among patients receiving chemotherapy: current state of the science.
Support Care Cancer
; 32(3): 184, 2024 Feb 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38393418
4.
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
N Engl J Med
; 382(20): 1894-1905, 2020 05 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32402160
5.
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.
Invest New Drugs
; 41(3): 421-430, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37074571
6.
Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma.
Curr Oncol Rep
; 25(10): 1191-1201, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37688739
7.
Metagenomics and chemotherapy-induced nausea: A roadmap for future research.
Cancer
; 128(3): 461-470, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34643945
8.
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
J Hepatol
; 76(4): 862-873, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34902530
9.
An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma.
Oncologist
; 27(10): 884-891, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35925597
10.
Risk Factors for Hospitalizations Among Older Adults with Gastrointestinal Cancers.
Oncologist
; 27(1): e37-e44, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35305099
11.
Patient-Defined Goals and Preferences Among Adults With Advanced Neuroendocrine Tumors.
J Natl Compr Canc Netw
; 20(12): 1330-1337.e3, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36509069
12.
A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE).
Future Oncol
; 18(40): 4465-4471, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36912078
13.
Diet quality indices and changes in cognition during chemotherapy.
Support Care Cancer
; 31(1): 75, 2022 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36544032
14.
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(7): 991-1001, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34051880
15.
A Comparison of Liver-Directed Therapy and Systemic Therapy for the Treatment of Liver Metastases in Patients with Gastrointestinal Neuroendocrine Tumors: Analysis of the California Cancer Registry.
J Vasc Interv Radiol
; 32(3): 393-402, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33358144
16.
Outcomes of neoadjuvant therapy for cholangiocarcinoma: A review of existing evidence assessing treatment response and R0 resection rate.
J Surg Oncol
; 123(1): 164-171, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32974932
17.
Lymphovascular Invasion Predicts Lymph Node Involvement in Small Pancreatic Neuroendocrine Tumors.
Neuroendocrinology
; 110(5): 384-392, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31401633
18.
Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma.
Int J Mol Sci
; 21(15)2020 Jul 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32718047
19.
Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival With or Without Liver Treatment.
Ann Surg
; 270(6): 1131-1137, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29746336
20.
Intrinsic brain activity changes associated with adjuvant chemotherapy in older women with breast cancer: a pilot longitudinal study.
Breast Cancer Res Treat
; 176(1): 181-189, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-30989462